As shares suf­fer from a lin­ger­ing slump, a bruised Alk­er­mes slash­es 160 jobs in R&D re­struc­tur­ing

With its share price in a deep slump af­ter suf­fer­ing through a reg­u­la­to­ry de­ba­cle over their de­pres­sion drug ALKS 5461, Alk­er­mes CEO Richard Pops is tak­ing the ax to its R&D or­ga­ni­za­tion in a re­struc­tur­ing aimed at cut­ting costs ahead of its next at­tempt at a roll­out in a tough field.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER